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19 Abstract 
SleepSight is a novel approach to detecting early signs 
of relapse in psychosis, thereby allowing targeted 
intervention for relapse prevention. The system uses a 
wireless-enabled wearable device and smartphone to 
collect longitudinal accelerometry, heart-rate, ambient 
light and smartphone usage patterns from patients 
living in their homes. These data are encrypted and 
sent via the mobile data network to a secure server for 
real-time analysis, using the Purple Robot mobile 
application.   
This study tested feasibility and acceptability of the 
SleepSight system in 15 participants with a diagnosis of 
schizophrenia. Patient recruitment and data collection 
was completed in January 2016, at the South London 
and Maudsley NHS Foundation Trust (SLaM), the 
largest mental health service provider in the EU. The 
project is a unique multidisciplinary collaboration 
between the NIHR Biomedical Research Centre for 
Mental Health, the Institute of Psychiatry, Psychology 
and Neuroscience, and the National Health Service. 
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Introduction 
Schizophrenia manifests itself as positive symptoms, 
including delusions, hallucinations and thought disorder 
as well as negative symptoms, including abnormal 
social behaviour and withdrawal. Therapeutic 
treatments often require an initial phase of dose 
adjustment to take effect and may result in a loss of 
drug efficacy, requiring dose readjustment with disease 
progression (Eisner, 2013). Around 80% of those 
treated for a first episode of psychosis relapse within 
five years (Robinson et al., 1999). This is partly due to 
limitations with self-reports, questionnaires and 
fortnightly or monthly screening as intervention 
measures in community based patients. 
Early signs of relapse in SchizophreniaMost relapse 
prevention strategies rely on self or observer-rated 
early warning signs (EWS) such as anxiety, dysphoria, 
and poor concentration that manifest prior to relapse 
(Eisner et al 2013). However, sensitivity and specificity 
have been modest, and are limited by infrequent 
assessment and loss of insight. Objective, physiological 
markers which can be sampled continuously are likely 
to have greater precision, place less burden on the user 
and thereby improve adherence, and allow passive 
monitoring to continue even once insight has been lost 
(Figure 1).  
In clinical practice, disturbance in normally rhythmically 
organised behaviours such as the sleep-wake cycle and 
activity and arousal levels are frequently observed in 
individuals presenting during relapse, and are cited in 
retrospect by patients and their carers as precursors to 
relapse (e.g. Herz et al 1980). Such disturbances are 
now readily measurable using accelerometers and 
optical heart-rate monitors embedded in wearable and 
mobile technologies, and may serve as clinically useful 
early indicators of relapse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A flowchart showing the 
consequences of insomnia and 
sleep deprivation, namely a 
progressively worsening 
psychosis in Schizophrenia 
patients. Using wearable devices 
and smartphone, this effect can 
be passively monitored and fed 
back to clinicians and care-teams. 
 
 
  
Methodology 
 
Study design 
The study involved the recruitment of 16 participants 
all of whom suffered from Schizophrenia. Each 
participant was given a smartphone (Nexus 5) as well 
as a wearable device (Fitbit Charge HR) and was 
monitored for a period of 8 weeks.  
The PANSS 
The positive and negative 
symptom scale (PANSS) is 
used to measure symptom 
severity in patients with 
Schizophrenia. The scale was 
introduced in 1987 and is 
now a widely used tool in the 
realm of antipsychotic 
therapy.  
 
Figure 2: The flowchart depicts 
the information flow between the 
different components of the 
SleepSight platform. The Fitbit 
Charge HR is transmitting its data 
to the smartphone (Nexus 5) via 
Bluetooth (BLE), from where it I 
uploaded to Fitbit’s servers. 
Accelerometer and light data as 
well as daily questionnaire 
submissions from the SleepSight 
app are directly uploaded to our 
KCL server from PurpleRobot. 
Once all data had been acquired, 
signal processing and anomaly 
detection was employed to 
identify a change in behavior 
  
Data acquisition 
The Purple Robot framework, developed by the Centre 
for Behavioural Intervention Technology (CBITS) at 
Northwestern University, provides an interface to on-
board mobile phone probes (e.g. gps, light, 
temperature) and a framework for integrating other 
mobile-aware probes e.g. wearables featuring 
accelerometers, oxygen saturation, heart rate, blood 
pressure, blood glucose. Using this platform, we have 
built a framework to enable patient reported outcome 
(PROM) data from smartphone applications, 
smartphone sensors and other sensor devices to be 
collected and analysed.  
The SleepSight platform 
The SleepSight platform was developed with the design 
criteria of device-agnosticism, reliability and user-
acceptance in mind (Figure 2). As result we decided to 
utilise the Fitbit Charge HR, featuring an optical heart 
rate sensor and accelerometer, as wearable. The Nexus 
5 had the Purple Robot and Fitbit mobile app installed 
to upload their data to our secure King’s College 
London (KCL)- and Fitbit’s server, respectively. 
Additionally, the phone featured a proprietary 
SleepSight app which would ask the participant to 
submit a sleep diary and PANSS-like questionnaire on a 
daily basis. The questionnaire data was used to 
complement the passively collected data set as labels. 
Finally, once the data arrived on our KCL server, we 
employed a probabilistic model to detect anomalies in 
each participant’s behavior, individually.  
Data analysis 
There are many ways to disseminate valuable 
information from a multivariate high resolution time 
series. In our case we wanted to prioritise 
quantification of our participant’s behavior and detect 
early signs of relapse.  
In order to achieve the latter, we trained a generalising 
Gaussian Process (GP) with a periodic (sinusoid) kernel 
on days on which a participant scored particularly low 
 symptom scores. Deviations from this model could then 
be quantified and evaluated (Figure 3). 
Results 
The study included 16 participants of which 14 
completed the study successfully based on our 
acceptability criteria of at least 70% wear-time and 
questionnaire submission over a period of 8 weeks 
(days n=56). Figure 4 shows user acceptance in more 
detail.  
Our GP anomaly detection methodology is still a work in 
progress and hence we are unable to present valuable 
results regarding behavior quantification at this point. 
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Figure 3: The plot depicts a 
Gaussian Process (grey band) 
trained on a participant’s heart 
rate time series (TS) on days with 
a low symptom score. The model 
is fitted over the entire day 
starting with wake time and 
ending with sleep, characterised 
by a lower heart rate. A 
smoothed heart rate TS from the 
test set is fitted on top of the 
model (blue curve) and the 
residual error is used to detect 
anomalies within this particular 
sample TS. 
 
Figure 4: The barchart depicts 
each participant’s wear-time 
(red), sleep diary (green) and 
symptoms submission (blue). 
